| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HEP.20410 |
| P698 | PubMed publication ID | 15382171 |
| P2093 | author name string | Cristina Longo | |
| Eduardo Fassio | |||
| Estela Alvarez | |||
| Graciela Landeira | |||
| Nora Domínguez | |||
| P2860 | cites work | Long term prognosis of fatty liver: risk of chronic liver disease and death. | Q35596463 |
| Nonalcoholic steatohepatitis: a study of 49 patients | Q38632482 | ||
| Nonalcoholic steatohepatitis: An expanded clinical entity | Q43036189 | ||
| Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities | Q43552270 | ||
| NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome | Q43875846 | ||
| Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis | Q44036847 | ||
| Progression of fibrosis in chronic hepatitis C. | Q44269259 | ||
| Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone | Q44598595 | ||
| A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis | Q44749300 | ||
| Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis | Q44880772 | ||
| The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years | Q45787554 | ||
| Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. | Q55033443 | ||
| NASH: from liver diseases to metabolic disorders and back to clinical hepatology. | Q64963481 | ||
| Two cases from the spectrum of nonalcoholic steatohepatitis | Q72283489 | ||
| Liver fibrosis in overweight patients | Q28145482 | ||
| Steatohepatitis: a tale of two "hits"? | Q29547771 | ||
| Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups | Q29614459 | ||
| Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity | Q29614914 | ||
| Histological grading and staging of chronic hepatitis | Q29619625 | ||
| Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease | Q30303621 | ||
| Hepatocellular carcinoma arising in non-alcoholic steatohepatitis | Q31907779 | ||
| Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study | Q34044074 | ||
| Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association | Q34112671 | ||
| Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease | Q34365693 | ||
| Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. | Q34525065 | ||
| Nonalcoholic fatty liver disease: an agenda for clinical research | Q34577550 | ||
| Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? | Q34598353 | ||
| Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? | Q34795935 | ||
| AGA technical review on nonalcoholic fatty liver disease | Q34982453 | ||
| Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference | Q35115696 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 820-826 | |
| P577 | publication date | 2004-10-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies | |
| P478 | volume | 40 |
| Q52651775 | A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. |
| Q40248747 | A study of gender-wise risk association between fatty liver and metabolic syndrome components (Asia-Pacific criteria) in a South Indian urban cohort |
| Q38374046 | Absorption, Distribution, Metabolism, and Excretion of [(14)C]-Volixibat in Healthy Men: Phase 1 Open-Label Study. |
| Q36432343 | Aliskiren Reduces Hepatic steatosis and Epididymal Fat Mass and Increases Skeletal Muscle Insulin Sensitivity in High-Fat Diet-Fed Mice |
| Q50615299 | Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis. |
| Q36328050 | An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). |
| Q39018492 | An estrogen receptor β-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors |
| Q36220756 | Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma. |
| Q34979933 | Animal models for the study of liver fibrosis: new insights from knockout mouse models |
| Q92983932 | Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice |
| Q42180658 | Apoptosis and diagnosis of nonalcoholic steatohepatitis. |
| Q38445611 | Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology |
| Q24240455 | Bariatric surgery for non-alcoholic steatohepatitis in obese patients |
| Q35890608 | Body iron, serum ferritin, and nonalcoholic fatty liver disease |
| Q46123445 | Centrilobular ductular reaction correlates with fibrosis stage and fibrosis progression in non-alcoholic steatohepatitis |
| Q36751382 | Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease |
| Q36750183 | Clinically significant chronic liver disease in people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study |
| Q85174809 | Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease |
| Q37660758 | Correlation of Body Mass Index and Serum Parameters With Ultrasonographic Grade of Fatty Change in Non-alcoholic Fatty Liver Disease |
| Q30385602 | Cost-utility analysis of nonalcoholic steatohepatitis screening. |
| Q33867312 | Cryptogenic cirrhosis in the region where obesity is not prevalent |
| Q50633557 | Development from simple steatosis to liver cirrhosis and hepatocellular carcinoma: a 27-year follow-up case. |
| Q64058237 | Development of a mouse iron overload-induced liver injury model and evaluation of the beneficial effects of placenta extract on iron metabolism |
| Q34036808 | Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B |
| Q30467234 | Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography |
| Q35064528 | Effect of lactulose on establishment of a rat non-alcoholic steatohepatitis model |
| Q37220903 | Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children |
| Q37405449 | Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. |
| Q35055531 | Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease |
| Q36288796 | Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases |
| Q35550630 | Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease |
| Q38207382 | Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies |
| Q36501848 | First-degree relatives of patients with type 2 diabetes mellitus and risk of non-alcoholic Fatty liver disease |
| Q92894259 | Free fatty acid-based low-impedance liver image: a characteristic appearance in nonalcoholic steatohepatitis (NASH) |
| Q90469547 | Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis |
| Q38167141 | Gastrointestinal complications of diabetes |
| Q34297858 | Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease |
| Q41872219 | Hepatic angiogenesis and fibrosis are common features in morbidly obese patients. |
| Q22305506 | Hepatic steatosis: a benign disease or a silent killer |
| Q51453492 | High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. |
| Q33602167 | Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis |
| Q36791363 | Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children |
| Q34306736 | Histopathology of nonalcoholic fatty liver disease |
| Q37220870 | Impact of obesity on the surgical outcome following repeat hepatic resection in Japanese patients with recurrent hepatocellular carcinoma |
| Q46220517 | Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study. |
| Q36763869 | Increased soluble leptin receptor levels in morbidly obese patients with insulin resistance and nonalcoholic fatty liver disease |
| Q38038107 | Influence of hepatic parenchymal histology on outcome following right hepatic trisectionectomy |
| Q26783727 | Insulin resistance, glucose intolerance and diabetes mellitus in obstructive sleep apnoea |
| Q37488800 | KASL clinical practice guidelines: management of nonalcoholic fatty liver disease |
| Q88554464 | Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging |
| Q26780252 | Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. |
| Q30403258 | MR Elastography of Liver Disease: State of the Art. |
| Q38867829 | MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice |
| Q35941934 | Managing nonalcoholic fatty liver disease: recommendations for family physicians. |
| Q34015290 | Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan |
| Q35209849 | Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly |
| Q42846205 | Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease |
| Q33755566 | Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH) |
| Q27007515 | Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH) |
| Q36367829 | Myeloperoxidase-Hepatocyte-Stellate Cell Cross Talk Promotes Hepatocyte Injury and Fibrosis in Experimental Nonalcoholic Steatohepatitis |
| Q36654473 | NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients |
| Q55514085 | Natural History of NAFLD/NASH. |
| Q38784787 | Natural History of Nonalcoholic Fatty Liver Disease |
| Q55155034 | Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies. |
| Q37078311 | Non alcoholic fatty liver disease and metabolic syndrome. |
| Q33789868 | Non-alcoholic fatty liver disease: An expanded review |
| Q27006131 | Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging |
| Q33616887 | Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments |
| Q37678998 | Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis |
| Q31004631 | Nonalcoholic Fatty Liver Disease: Correlation of the Liver Parenchyma Fatty Acid with Intravoxel Incoherent Motion MR Imaging-An Experimental Study in a Rat Model |
| Q36796030 | Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance |
| Q89377158 | Nonalcoholic Fatty Liver Disease: Time to Take the Bull by the Horns |
| Q26827169 | Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians? |
| Q30622511 | Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data |
| Q37699734 | Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment |
| Q37632281 | Nonalcoholic fatty liver disease in children living in the obeseogenic society |
| Q24563381 | Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic |
| Q37681360 | Nonalcoholic fatty liver disease: a review and update |
| Q38074898 | Nonalcoholic fatty liver disease: current issues and novel treatment approaches |
| Q55401392 | Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. |
| Q38290119 | Nonalcoholic steatohepatitis and insulin resistance in children |
| Q26746997 | Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis |
| Q35200808 | Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease |
| Q34760318 | Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice |
| Q64245215 | Paradoxical Roles of Oxidative Stress Response in the Digestive System before and after Carcinogenesis |
| Q36179902 | Pathogenesis and management issues for non-alcoholic fatty liver disease |
| Q34390296 | Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge |
| Q42277188 | Placental extract ameliorates non-alcoholic steatohepatitis (NASH) by exerting protective effects on endothelial cells |
| Q35380845 | Potential epigenetic mechanism in non-alcoholic Fatty liver disease |
| Q33891750 | Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease |
| Q37708418 | Probiotics and Nonalcoholic Fatty liver Disease |
| Q38090905 | Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis |
| Q33863032 | Progression of diet induced nonalcoholic steatohepatitis is accompanied by increased expression of Kruppel-like-factor 10 in mice |
| Q30375693 | Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. |
| Q34464043 | Recent advances in the development of farnesoid X receptor agonists |
| Q57170235 | Recent research trends and updates on nonalcoholic fatty liver disease |
| Q28607750 | Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis |
| Q47399864 | Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. |
| Q36613681 | Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells |
| Q30433234 | Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. |
| Q47367170 | Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome |
| Q28079820 | The Effect of Bariatric Surgery on the Spectrum of Fatty Liver Disease |
| Q26746947 | The Natural Course of Non-Alcoholic Fatty Liver Disease |
| Q35100100 | The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis |
| Q83195671 | The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis |
| Q42838234 | The role of the gut microbiota in nonalcoholic fatty liver disease |
| Q24655572 | Treatment of non-alcoholic fatty liver disease |
| Q35536468 | Turnover rates of hepatic collagen and circulating collagen-associated proteins in humans with chronic liver disease |
| Q39034740 | Upregulated absorption of dietary palmitic acids with changes in intestinal transporters in non-alcoholic steatohepatitis (NASH). |
| Q35551319 | Usefulness of the controlled attenuation parameter for detecting liver steatosis in health checkup examinees |
| Q80194076 | Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study |
| Q36280695 | ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population |
| Q52592635 | [11C]acetate PET as a tool for diagnosis of liver steatosis. |
Search more.